Skip to main content
Erschienen in: Rheumatology International 12/2021

24.09.2021 | Observational Research

Are YouTube videos enough to learn anakinra self-injection?

verfasst von: Melih Pamukcu, Tugba Izci Duran

Erschienen in: Rheumatology International | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Anakinra is a drug that can be administered subcutaneously as a self-injection in both children and adults. We aimed to evaluate the content, reliability, and quality of the videos most viewed on “anakinra self-injection” on YouTube, which is an easily accessible source of information. We performed a YouTube search using the keywords “anakinra”, “anakinra injection”, and “anakinra self-injection” in addition to the generic and commercial names of the biologic agent in September 2021. The quality and reliability of the videos were assessed according to the Global Quality Score (GQS) and DISCERN score. Video power index was used to assess both the view and the like ratio of the videos. A total of 51 videos were analyzed, a majority of which were uploaded by physicians (56.9%). The median GQS was 3 and total DISCERN score was 49. According to the GQS, 21.6% of the videos were of low quality, 35.3% were of fair quality, and 43.1% were of high quality. High-quality videos had higher DISCERN scores and longer duration of videos (p < 0.05). 41 (80.4%) videos were categorized as useful information, and 8 (15.7%) as useful as per patients’ opinion. Further, GQS and DISCERN scores of videos that had useful information were significantly higher. There are numerous YouTube videos with helpful information that can be a source of knowledge on the safe and correct technique of daily anakinra self-injection for both adults and children. There was no significant difference in patient interaction between useful and misleading videos. This indicates that patients do not differentiate between high- and low-quality videos.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A (2016) Effect of Anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP Randomized Clinical Trial. JAMA 316(18):1906–1912. https://doi.org/10.1001/jama.2016.15826CrossRefPubMed Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A (2016) Effect of Anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP Randomized Clinical Trial. JAMA 316(18):1906–1912. https://​doi.​org/​10.​1001/​jama.​2016.​15826CrossRefPubMed
2.
Zurück zum Zitat Ter Haar NM, Eijkelboom C, Cantarini L, Papa R, Brogan PA, Kone-Paut I, Modesto C, Hofer M, Iagaru N, Fingerhutová S, Insalaco A, Licciardi F, Uziel Y, Jelusic M, Nikishina I, Nielsen S, Papadopoulou-Alataki E, Olivieri AN, Cimaz R, Susic G, Stanevica V, van Gijn M, Vitale A, Ruperto N, Frenkel J, Gattorno M (2019) Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Ann Rheum Dis 78(10):1405–1411. https://doi.org/10.1136/annrheumdis-2018-214472CrossRefPubMed Ter Haar NM, Eijkelboom C, Cantarini L, Papa R, Brogan PA, Kone-Paut I, Modesto C, Hofer M, Iagaru N, Fingerhutová S, Insalaco A, Licciardi F, Uziel Y, Jelusic M, Nikishina I, Nielsen S, Papadopoulou-Alataki E, Olivieri AN, Cimaz R, Susic G, Stanevica V, van Gijn M, Vitale A, Ruperto N, Frenkel J, Gattorno M (2019) Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Ann Rheum Dis 78(10):1405–1411. https://​doi.​org/​10.​1136/​annrheumdis-2018-214472CrossRefPubMed
3.
Zurück zum Zitat Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen T, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar M (2019) Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/key402CrossRef Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen T, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar M (2019) Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). https://​doi.​org/​10.​1093/​rheumatology/​key402CrossRef
4.
Zurück zum Zitat Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, Placebo-Controlled Trial. Arthritis Rheumatol 69(4):854–862. https://doi.org/10.1002/art.39995CrossRefPubMed Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, Placebo-Controlled Trial. Arthritis Rheumatol 69(4):854–862. https://​doi.​org/​10.​1002/​art.​39995CrossRefPubMed
5.
Zurück zum Zitat Cimaz R, Maioli G, Calabrese G (2020) Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 20(7):725–740CrossRefPubMed Cimaz R, Maioli G, Calabrese G (2020) Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 20(7):725–740CrossRefPubMed
7.
Zurück zum Zitat Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2(6):e325–e331. https://doi.org/10.1016/s2665-9913(20)30127-2CrossRefPubMedPubMedCentral Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2(6):e325–e331. https://​doi.​org/​10.​1016/​s2665-9913(20)30127-2CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kaicker J, Debono VB, Dang W, Buckley N, Thabane L (2010) Assessment of the quality and variability of health information on chronic pain websites using the DISCERN instrument. BMC Med 8(1):1–8CrossRef Kaicker J, Debono VB, Dang W, Buckley N, Thabane L (2010) Assessment of the quality and variability of health information on chronic pain websites using the DISCERN instrument. BMC Med 8(1):1–8CrossRef
17.
Zurück zum Zitat Weil AG, Bojanowski MW, Jamart J, Gustin T, Lévêque M (2014) Evaluation of the quality of information on the Internet available to patients undergoing cervical spine surgery. World Neurosurg 82(1–2):e31–e39CrossRefPubMed Weil AG, Bojanowski MW, Jamart J, Gustin T, Lévêque M (2014) Evaluation of the quality of information on the Internet available to patients undergoing cervical spine surgery. World Neurosurg 82(1–2):e31–e39CrossRefPubMed
18.
Metadaten
Titel
Are YouTube videos enough to learn anakinra self-injection?
verfasst von
Melih Pamukcu
Tugba Izci Duran
Publikationsdatum
24.09.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 12/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04999-w

Weitere Artikel der Ausgabe 12/2021

Rheumatology International 12/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.